Navigation Links
Genaera Discontinues Lomucin in Cystic Fibrosis Studies

Genaera Corporation announced that, in conjunction with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), both parties have agreed for reasons of futility to discontinue the Phase 2 study of LOMUCIN(TM) for the treatment of cystic fibrosis (CF). Genaera also announced that the Phase 2 study of squalamine in prostate cancer, which is an investigator-initiated study funded by the Department of Defense, will also be discontinued.

"Earlier this year we redefined our business strategy and committed to focus our efforts on our two core assets, trodusquemine (MSI-1436) for obesity and the anti-IL-9 (MEDI-528) program licensed to MedImmune, Inc. for the treatment of asthma, and continue efforts to monetize our non-core assets. Our announcement today is consistent with that strategy and serves as validation that we are executing upon it," stated Jack Armstrong, President and CEO of Genaera.

Mr. Armstrong continued, "We continue to be very encouraged by the progress of the MEDI-528 Phase 2 program in asthma. This is an asset that is below the radar screen of many, and we believe has greater present and future value than is currently recognized by the market. Separately, our trodusquemine Phase 1 study in obesity is progressing nicely through the initial cohorts in Study 101 to test safety and PK. We believe this program, in addition to anti-IL-9, will generate significant additional interest in the Company in the near future as additional data becomes available."

As a result of the joint decision to terminate the LOMUCIN study, the CFFT has agreed to final financial details of the award agreement to support the evaluation of LOMUCIN in subjects with CF. Genaera will receive a final milestone payment in the amount of $100,000 and will not be required to refund any portion of the award previously received from the CFFT. As a result of termination, the Company will recognize revenue of $2,102,000 of which $2,002,000 was previously r ecorded as a long-term liability.

Termination of the LOMUCIN study was a result of a recommendation by the Company to the study's Data Monitoring Committee (DMC) to close the ongoing study for futility. The DMC identified no safety concerns in their review.

"Genaera and the Data Monitoring Committee planned a joint evaluation of the midpoint data from the LOMUCIN study to determine if the enrollment of the final subjects in the study would allow us to better understand the impact of the drug on respiratory function in cystic fibrosis patients. The committee determined that there is no additional benefit to further enrollment, so we found it reasonable to conclude the study, evaluate the impact of the drug, and move forward focused on our core programs," stated Michael J. Gast, M.D., Ph.D., Executive Vice President of Clinical Research and Development at Genaera. "We believe that the data from this LOMUCIN study continues to validate the drug's target, hCLCA1, as a potential target for future research in respiratory and other diseases and we maintain a strong intellectual property position and library of over 15,000 compounds for this target."

The Phase 2 study of squalamine in prostate cancer, another of Genaera's non-core assets, was also discontinued. There had been no recent enrollment in this trial, and delays in restarting the study at a new investigative site made the decision to end the study appropriate.


'"/>




Related medicine news :

1. Gene Therapy For Cystic Fibrosis
2. Surprising Cystic Fibrosis Finding That Could Be A Helpful Treatment Option
3. The Use Of Colistin To Treat Cystic Fibrosis Questioned
4. Cystic fibrosis patients may require a new treatment for bacterial infection
5. Treatment for Cystic Fibrosis in the future
6. New Therapy Discovered By Scientists For Cystic Fibrosis
7. Inhaling Concentrated Saline Could Benefit Cystic Fibrosis Patients
8. New Multi-functional Sensing Tool To Investigate Cystic Fibrosis
9. Protein May Offer New Hope For Treatment Of Cystic Fibrosis
10. Cellular System Causing Destruction Of Faulty Proteins In Cystic Fibrosis Identified
11. Gene Therapy To The Aid Of Cystic Fibrosis.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... needy individuals and families from eight different sites throughout Miami-Dade and Broward counties. ... 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual meals ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: ... of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon ... of Water, Global Climate Change and Your Health radio program syndicated on Voice ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... that we have been designated as a Cigna Infertility Center of Excellence. The ... performance standards. , “It’s an honor to be designated a Cigna Infertility ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... 2, 2016 Boston Scientific Corporation (NYSE: ... acquire certain manufacturing assets and capabilities of the Neovasc, ... biological tissue business, as well as a 15% equity ... in cash. The Neovasc advanced biological tissue business makes ... Scientific Lotus™ Valve System. * Upon completion of ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite ended ... Industrial Average edged 0.36% higher, to finish at 19,191.93; and ... broad based as six out of nine sectors ended the ... the following Services equities: Myriad Genetics Inc. (NASDAQ: ... Research Holdings Inc. (NASDAQ: INCR ), and La ...
Breaking Medicine Technology: